| Primary |
| Renal Transplant |
89.8% |
| Immunosuppression |
3.4% |
| Hypertension |
2.7% |
| Prophylaxis Against Transplant Rejection |
1.7% |
| Antiviral Prophylaxis |
0.7% |
| Pyrexia |
0.7% |
| Constipation |
0.3% |
| Metabolic Acidosis |
0.3% |
| Pain |
0.3% |
|
| Kidney Transplant Rejection |
45.9% |
| Pneumonia |
7.4% |
| Respiratory Failure |
4.9% |
| Transplant Rejection |
4.9% |
| Prostate Cancer |
4.1% |
| Pulmonary Oedema |
3.3% |
| Sepsis |
3.3% |
| Squamous Cell Carcinoma Of Skin |
3.3% |
| Arteriovenous Fistula Site Complication |
2.5% |
| Basal Cell Carcinoma |
2.5% |
| Pneumocystis Jiroveci Pneumonia |
2.5% |
| Pyrexia |
2.5% |
| Cellulitis |
1.6% |
| Hepatic Function Abnormal |
1.6% |
| Lung Cancer Metastatic |
1.6% |
| Metastases To Central Nervous System |
1.6% |
| Metastases To Liver |
1.6% |
| Multi-organ Failure |
1.6% |
| Myelodysplastic Syndrome |
1.6% |
| Non-small Cell Lung Cancer |
1.6% |
|
| Secondary |
| Renal Transplant |
68.2% |
| Liver Transplant |
12.5% |
| Immunosuppression |
5.8% |
| Product Used For Unknown Indication |
5.0% |
| Prophylaxis Against Transplant Rejection |
3.6% |
| Drug Use For Unknown Indication |
1.6% |
| Immunosuppressant Drug Therapy |
1.1% |
| Hypertension |
0.4% |
| Aspergillosis |
0.3% |
| Type 1 Diabetes Mellitus |
0.3% |
| Antibiotic Therapy |
0.1% |
| Antiviral Prophylaxis |
0.1% |
| Bladder Disorder |
0.1% |
| Blood Cholesterol |
0.1% |
| Cytomegalovirus Viraemia |
0.1% |
| Gastrooesophageal Reflux Disease |
0.1% |
| Haemolytic Uraemic Syndrome |
0.1% |
| Liver Transplant Rejection |
0.1% |
| Oedema Peripheral |
0.1% |
| Osteoporosis Prophylaxis |
0.1% |
|
| Urinary Tract Infection |
17.8% |
| Sepsis |
7.4% |
| Pneumonia |
6.1% |
| Squamous Cell Carcinoma Of Skin |
6.1% |
| Urosepsis |
6.1% |
| Renal Failure Acute |
4.9% |
| Basal Cell Carcinoma |
4.3% |
| Respiratory Distress |
4.3% |
| Respiratory Moniliasis |
4.3% |
| Squamous Cell Carcinoma |
4.3% |
| Transient Ischaemic Attack |
4.3% |
| Weight Decreased |
4.3% |
| Bronchopneumonia |
3.7% |
| Wound Infection |
3.7% |
| Cytomegalovirus Infection |
3.1% |
| Graft Dysfunction |
3.1% |
| Oesophageal Squamous Cell Carcinoma |
3.1% |
| Pleural Effusion |
3.1% |
| Pneumonia Aspiration |
3.1% |
| Pulmonary Tuberculosis |
3.1% |
|
| Concomitant |
| Renal Transplant |
67.9% |
| Immunosuppression |
13.7% |
| Product Used For Unknown Indication |
4.6% |
| Prophylaxis Against Transplant Rejection |
3.1% |
| Immunosuppressant Drug Therapy |
2.3% |
| Tuberculosis |
2.3% |
| Haemolytic Uraemic Syndrome |
1.5% |
| Antibiotic Prophylaxis |
0.8% |
| Hyperparathyroidism Secondary |
0.8% |
| Hypertension |
0.8% |
| Infection Prophylaxis |
0.8% |
| Kidney Transplant Rejection |
0.8% |
| Peritonitis |
0.8% |
|
| Blood Creatinine Increased |
12.1% |
| Renal Transplant |
12.1% |
| Skin Burning Sensation |
12.1% |
| Urosepsis |
9.1% |
| Brain Abscess |
6.1% |
| Complications Of Transplanted Kidney |
6.1% |
| Thrombotic Microangiopathy |
6.1% |
| Transplant Failure |
6.1% |
| Urine Output Decreased |
6.1% |
| Haemoglobin Decreased |
3.0% |
| Hepatitis |
3.0% |
| Jaundice |
3.0% |
| Right Ventricular Failure |
3.0% |
| Sepsis |
3.0% |
| Toxicity To Various Agents |
3.0% |
| Transplant Rejection |
3.0% |
| White Blood Cell Count Decreased |
3.0% |
|
| Interacting |
|
| Kidney Transplant Rejection |
100.0% |
|
